glp-1 articles Frontiers Glucagon-like peptide-1 receptor: mechanisms and

Who Needs It

No trademark use here implies endorsement by or affiliation with those trademark holders

Onceweekly albiglutide versus oncedaily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, openlabel, multicentre, noninferiority phase 3 study

Tirzepatide is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, while other medications in this class activate only GLP-1 receptors

For a 220-pound person, thats 33 pounds with semaglutide versus 53 pounds with retatrutide

Although data from early phase trials suggest that retatrutide is well tolerated with a similar adverse event profile to GLP-1 RAs, additional research assessing long-term safety and efficacy of retatrutide in people living with obesity and/or T2D (including cardiovascular outcomes) is awaited over the next five years